<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402018000100039</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2017.02.005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Vasopresores e inotrópicos: uso en pediatría]]></article-title>
<article-title xml:lang="en"><![CDATA[Vasopressors and inotropes: use in paediatrics]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Canales]]></surname>
<given-names><![CDATA[Adrián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peña-Juárez]]></surname>
<given-names><![CDATA[Rocío Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sandoval-Franco]]></surname>
<given-names><![CDATA[Luz de María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Regional Valentín Gómez Farías ]]></institution>
<addr-line><![CDATA[Zapopan Jalisco]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital General de Occidente  ]]></institution>
<addr-line><![CDATA[Zapopan Jalisco]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Climosal  ]]></institution>
<addr-line><![CDATA[Santa Tecla La Libertad]]></addr-line>
<country>El Salvador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<volume>88</volume>
<numero>1</numero>
<fpage>39</fpage>
<lpage>50</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402018000100039&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402018000100039&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402018000100039&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El sistema cardiovascular es un sistema dinámico cuya función es asegurar un adecuado suministro de oxígeno, nutrientes y hormonas a los tejidos, necesarios para el metabolismo celular, además sintetiza y modifican los componentes vasoactivos los cuales regulan el tono vascular y la función miocárdica. Estos componentes vasoactivos son fundamentales en el manejo del paciente pediátrico en estado crítico con falla cardiaca y choque en los cuales se ha comprobado sus efectos benéficos, sin embargo, su uso y abuso trae consigo efectos nocivos, tales como mayor riesgo de arritmias, aumento el consumo miocárdico de oxígeno lo cual podría favorecer la presencia de isquemia. Por lo tanto, es preciso conocer el mecanismo de acción de los distintos tipos de agentes vasoactivos, así como las indicaciones de dichos fármacos para minimizar dichos efectos. El propósito de esta revisión es describir la farmacología y las aplicaciones clínicas de los agentes inotrópicos y Vasopresores en el paciente pediátrico en estado crítico. © 2017 Instituto Nacional de Cardiolog´&#305;a Ignacio Cha´vez. Publicado por Masson Doyma Me´xico S.A. Este es un art´&#305;culo Open Access bajo la licencia CC BY-NC-ND (https://creativecommons.org/licenses/by-nc-nd/4.0/).]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: The cardiovascular system is a dynamic system, which is required to ensure adequate delivery of oxygen, nutrients, and hormones to the tissues that are necessary for cell metabolism. It also synthesises and modifies the vasoactive components that regulate vascular tone and myocardial function. These vasoactive components have demonstrated their beneficial effects in the management of paediatric patients in a critical condition with heart failure and shock. However, their use and abuse brings harmful effects, increases mortality, and is associated with arrhythmias. An increase in myocardial oxygen consumption favours the presence of ischaemia, therefore it is necessary to know the mechanism of action and indications of these drugs to minimise their harmful effects. The purpose of this review is to describe the pharmacology and clinical applications of inotropic and vasopressor agents in the paediatric patient in acritical condition. © 2017 Instituto Nacional de Cardiologìa Ignacio Chàvez. Published by Masson Doyma Mèxico S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Falla cardiaca]]></kwd>
<kwd lng="es"><![CDATA[Choque]]></kwd>
<kwd lng="es"><![CDATA[Inotrópicos]]></kwd>
<kwd lng="es"><![CDATA[Vasopresores]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[Heart failure]]></kwd>
<kwd lng="en"><![CDATA[Shock]]></kwd>
<kwd lng="en"><![CDATA[Inotropes]]></kwd>
<kwd lng="en"><![CDATA[Vasopressors]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[de Backer]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulatory shock.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>369</volume>
<page-range>1726-34</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKiernan]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Lieberman]]></surname>
<given-names><![CDATA[SA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulatory shock.]]></article-title>
<source><![CDATA[Pediatr Rev.]]></source>
<year>2005</year>
<volume>26</volume>
<page-range>451-60</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noori]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Seri]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neonatal blood pressure support: The use of inotropes, lusitropes, and other vasopressor agents.]]></article-title>
<source><![CDATA[Clin Perinatol.]]></source>
<year>2012</year>
<volume>39</volume>
<page-range>221-38</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Backer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Creteur]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dubois]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects.]]></article-title>
<source><![CDATA[Crit Care Med.]]></source>
<year>2006</year>
<volume>34</volume>
<page-range>403-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elkayam]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Tasissa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Binanay]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.]]></article-title>
<source><![CDATA[Am Heart J.]]></source>
<year>2007</year>
<volume>153</volume>
<page-range>98-104</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Bartos]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Adatya]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inotropes]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>63</volume>
<page-range>2069-78</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollenberg]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inotrope and vasopressor therapy of septic shock.]]></article-title>
<source><![CDATA[Crit Care Nursing Clin N Am.]]></source>
<year>2011</year>
<volume>23</volume>
<page-range>127-48</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ellender]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[JC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of vasopressors and inotropes in the emergency medical treatment of shock.]]></article-title>
<source><![CDATA[Emerg Med Clin N Am.]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>59-86</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Timmins]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Yau]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevation of systemic oxygen delivery in the treatment of critically ill patients.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1994</year>
<volume>330</volume>
<page-range>1717-22</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivers]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Havstad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early goal-directed therapy in the treatment of severe sepsis and septic shock.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>1368-77</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gattinoni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brazzi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pelosi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1995</year>
<volume>333</volume>
<page-range>1025-32</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bangash]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Pear]]></surname>
<given-names><![CDATA[RM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use inotropes and vasopressors in the critically ill.]]></article-title>
<source><![CDATA[Br J Pharmacol.]]></source>
<year>2012</year>
<volume>165</volume>
<page-range>2015-33</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simmons]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Durham]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[CW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological management of pediatric patients with sepsis.]]></article-title>
<source><![CDATA[AACN Adv Crit Care.]]></source>
<year>2012</year>
<volume>23</volume>
<page-range>437-48</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[DeBlieux]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pressors and inotropes.]]></article-title>
<source><![CDATA[Emerg Med Clin North Am.]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>823-34</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Connell]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[PC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alpha-1-adrenergic receptors in heart failure: The adaptive arm of the cardiac response to chronic catecholamine stimulation.]]></article-title>
<source><![CDATA[J Cardiovasc Pharmacol.]]></source>
<year>2014</year>
<volume>63</volume>
<page-range>291-301</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagashima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hattori]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Akaishi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alpha 1-adrenoceptor subtypes mediating inotropic and electrophysiological effects in mammalian myocardium.]]></article-title>
<source><![CDATA[Am J Phys.]]></source>
<year>1996</year>
<volume>271</volume>
<page-range>H1423-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruffolo JR]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stadel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological and therapeutic applications of alpha2-adrenoceptor subtypes.]]></article-title>
<source><![CDATA[Annu Rev Pharmacol Toxicol.]]></source>
<year>1993</year>
<volume>32</volume>
<page-range>243-79</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vasopressor agents: Old and new components.]]></article-title>
<source><![CDATA[Curr Opin Crit Care.]]></source>
<year>2004</year>
<volume>10</volume>
<page-range>183-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steele]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bihari]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Choice of catecholamine: Does it matter?]]></article-title>
<source><![CDATA[Curr Opin Crit Care.]]></source>
<year>2000</year>
<volume>6</volume>
<page-range>347-53</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Girault]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Greengard]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The neurobiology of dopamine signaling.]]></article-title>
<source><![CDATA[Arch Neurol.]]></source>
<year>2004</year>
<volume>61</volume>
<page-range>641-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jose]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Eisner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Felder]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulation of blood pressure by dopamine receptors.]]></article-title>
<source><![CDATA[Nephron Physiol.]]></source>
<year>2003</year>
<volume>95</volume>
<page-range>19-27</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Landry]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Granton]]></surname>
<given-names><![CDATA[JT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Science review. Vasopressin and the cardiovascular system part I- Receptor physiology.]]></article-title>
<source><![CDATA[Crit Care.]]></source>
<year>2003</year>
<volume>7</volume>
<page-range>427-34</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le Tulzo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Seguin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gacouin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of epinephrine on right ventricular function in patients with severe septic shock and right ventricular failure: A preliminary study.]]></article-title>
<source><![CDATA[Intensive Care Med.]]></source>
<year>1997</year>
<volume>23</volume>
<page-range>664-70</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bollaert]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Audibert]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine- resistant septic shock.]]></article-title>
<source><![CDATA[Chest]]></source>
<year>1990</year>
<volume>98</volume>
<page-range>949-53</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Backer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Creteur]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best?]]></article-title>
<source><![CDATA[Crit Care Med.]]></source>
<year>2003</year>
<volume>31</volume>
<page-range>1659-67</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Butterworth]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Prielipp]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Royster]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dobutamine increases heart rate more than epinephrine in patients recovering from aortocoronary bypass surgery.]]></article-title>
<source><![CDATA[J Cardiothorac Vasc Anesth.]]></source>
<year>1992</year>
<volume>6</volume>
<page-range>535-41</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Annane]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vignon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Renault]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2007</year>
<volume>370</volume>
<page-range>676-84</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bassi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[LC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic strategies for highdose vasopressor-dependent shock.]]></article-title>
<source><![CDATA[Crit Care Res Pract.]]></source>
<year>2013</year>
<volume>2013</volume>
<page-range>654-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nasraway]]></surname>
<given-names><![CDATA[SA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Norepinephrine: no more &#8216;&#8216;leave&#8217;em dead&#8217;&#8217;?]]></article-title>
<source><![CDATA[Crit Care Med.]]></source>
<year>2000</year>
<volume>28</volume>
<page-range>3096-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Viviand]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Leone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of norepinephrine on the outcome of septic shock.]]></article-title>
<source><![CDATA[Crit Care Med.]]></source>
<year>2000</year>
<volume>28</volume>
<page-range>2758-65</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Werdan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Russ]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Buerke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiogenic shock due to myocardial infarction: Diagnosis, monitoring and treatment: A German-Austrian S3 Guideline.]]></article-title>
<source><![CDATA[Deutsch Arztebl Int.]]></source>
<year>2012</year>
<volume>109</volume>
<page-range>343-51</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feneck]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phosphodiesterase inhibitors and the cardiovascular system.]]></article-title>
<source><![CDATA[Contin Educ Anaesth Crit Care Pain.]]></source>
<year>2007</year>
<volume>7</volume>
<page-range>203-7</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Overgaard]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Dzavik]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inotropes and vasopressors. Review of physiology and clinical use in cardiovascular disease.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>118</volume>
<page-range>1047-56</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paradisis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kluckow]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants.]]></article-title>
<source><![CDATA[J Pediatr.]]></source>
<year>2009</year>
<volume>154</volume>
<page-range>189-95</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Khuffash]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weisz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assesment and treatment of post patent ductus arteriosus ligation syndrome.]]></article-title>
<source><![CDATA[J Pediatr.]]></source>
<year>2014</year>
<volume>165</volume>
<page-range>46-52</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samiee-Zafarghandy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Raman]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[van den Anker]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of milrinone in neonatal intensive care units.]]></article-title>
<source><![CDATA[Early Human Dev.]]></source>
<year>2015</year>
<volume>91</volume>
<page-range>31-5</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cariou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pinsky]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Monchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is myocardial adrenergic responsiveness depressed in human septic shock?]]></article-title>
<source><![CDATA[Intensive Care Med.]]></source>
<year>2008</year>
<volume>34</volume>
<page-range>917-22</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silver]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intermittent inotropes for advanced heart failure: Inquiring minds want to know.]]></article-title>
<source><![CDATA[Am Heart J.]]></source>
<year>1999</year>
<volume>138</volume>
<page-range>191-2</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jentzer]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Coons]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Link]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.]]></article-title>
<source><![CDATA[J Cardiovasc Pharmacol Ther.]]></source>
<year>2015</year>
<volume>20</volume>
<page-range>249-60</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollenberg]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vasoactive drugs in circulatory shock.]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med.]]></source>
<year>2011</year>
<volume>183</volume>
<page-range>847-55</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollenberg]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recognition and treatment of cardiogenic shock.]]></article-title>
<source><![CDATA[Semin Respir Crit Care Med.]]></source>
<year>2004</year>
<volume>25</volume>
<page-range>661-71</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Bigham]]></surname>
<given-names><![CDATA[MT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiogenic shock.]]></article-title>
<source><![CDATA[Open Pediatr Med J.]]></source>
<year>2013</year>
<volume>7</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>19-27</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wernosky]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Atz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2003</year>
<volume>107</volume>
<page-range>996-1002</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burkhardt]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Rücker]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Stiller]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prophylactic milrinone for prevention of low cardiac output syndrome and mortality in children urdergoing surgery for congenital heart disease.]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev.]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of the off-label use of milrinone in pediatric patients with heart diseases.]]></article-title>
<source><![CDATA[Korean Circ J.]]></source>
<year>2014</year>
<volume>44</volume>
<page-range>320-7</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Owen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Borgman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relation of milrinone following surgery for congenital heart disease to significant postoperative tachyarrhytmias.]]></article-title>
<source><![CDATA[Am J Cardiol.]]></source>
<year>2011</year>
<volume>108</volume>
<page-range>1620-4</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buck]]></surname>
<given-names><![CDATA[ML.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of milrinone in infants and children.]]></article-title>
<source><![CDATA[Pediatr Pharm.]]></source>
<year>2003</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B48">
<label>48.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Km]]></surname>
<given-names><![CDATA[Gist]]></given-names>
</name>
<name>
<surname><![CDATA[t]]></surname>
<given-names><![CDATA[Mizuno]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury.]]></article-title>
<source><![CDATA[Ther Drug Monit.]]></source>
<year>2015</year>
<volume>37</volume>
<page-range>792-6</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
<name>
<surname><![CDATA[Bautista]]></surname>
<given-names><![CDATA[HV.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inodilators in the management of low cardiac output syndrome after pediatric cardiac surgery.]]></article-title>
<source><![CDATA[Curr Vasc Pharmacol.]]></source>
<year>2016</year>
<volume>14</volume>
<page-range>48-57</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toller]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Algotsson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Guarracino]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perioperative use of levosimendan: Best practice in operative settings.]]></article-title>
<source><![CDATA[J Cardiothoracic Vascular Anesth.]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>361-6</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kivikko]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lehtonen]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levosimendan: A new inodilatador drug for the treatment of decompensated heart failure.]]></article-title>
<source><![CDATA[Current Pharma Des.]]></source>
<year>2005</year>
<volume>11</volume>
<page-range>435-55</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papp]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Edes]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fruhwad]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levosimendan: Molecular mechanism and clinical impications: Consensus of experts on the mechanisms of action of levosimendan.]]></article-title>
<source><![CDATA[Int J Cardiol.]]></source>
<year>2012</year>
<volume>159</volume>
<page-range>82-7</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Szilagyi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pollesello]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Levijoki]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the Guinea pig.]]></article-title>
<source><![CDATA[Eur J Pharmacol.]]></source>
<year>2004</year>
<volume>486</volume>
<page-range>67-74</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antoniades]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tousoulis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Koumallos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levosimendan: Beyond its simple inotropic effect in heart failure.]]></article-title>
<source><![CDATA[Pharmacol Ther.]]></source>
<year>2007</year>
<volume>114</volume>
<page-range>184-97</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Givertz]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Andreou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Conrad]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: Alteration of force-frecuency and relaxation-frecuency relationships.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>115</volume>
<page-range>1218-24</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[YB]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[MX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A structural and functional perspective into the mechanism of Ca sensitizers that target the cardiac troponin complex.]]></article-title>
<source><![CDATA[J Mol Cell Cardiol.]]></source>
<year>2010</year>
<volume>49</volume>
<page-range>1031-41</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Peart]]></surname>
<given-names><![CDATA[JN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[KATP channels and myocardial preconditioning: An update.]]></article-title>
<source><![CDATA[AM J Physiol Heart Circ Physiol.]]></source>
<year>2003</year>
<volume>285</volume>
<page-range>H921-30</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pollesello]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Papp]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cardioprotective effects of levosimendan: Preclinical and clinical evidence.]]></article-title>
<source><![CDATA[J Cardiovasc Pharmacol.]]></source>
<year>2007</year>
<volume>50</volume>
<page-range>257-63</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kowaltowski]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Seetharamn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Paucek]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioenergetic consequences of opening the ATP-sensitive K (+) channel of heart mitochondria.]]></article-title>
<source><![CDATA[Am J Physiol Heart Circ Physiol.]]></source>
<year>2001</year>
<volume>280</volume>
<page-range>H649-57</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rohel]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Loetscher]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Rossaint]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury.]]></article-title>
<source><![CDATA[BMC Neurol]]></source>
<year>2010</year>
<volume>21</volume>
<page-range>97</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pellicer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Riera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[OP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery.]]></article-title>
<source><![CDATA[Pediatr Res]]></source>
<year>2013</year>
<volume>73</volume>
<page-range>95-103</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ricci]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Garisto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Favia]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levosimendan infusión in newborns after corrective surgery for congenital heart disease: Randomized controlled trial.]]></article-title>
<source><![CDATA[Intensive Care Med.]]></source>
<year>2012</year>
<volume>38</volume>
<page-range>1198-204</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silvetti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Silvani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Azzolini]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review on levosimendan in paediatric patients.]]></article-title>
<source><![CDATA[Curr Vasc Pharmacol.]]></source>
<year>2015</year>
<volume>13</volume>
<page-range>128-33</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Namachivayam]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Crossland]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Butt]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early experience with levosimendan in children with ventricular dysfunction.]]></article-title>
<source><![CDATA[Pediatr Crit Care Med]]></source>
<year>2006</year>
<volume>7</volume>
<page-range>445-8</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryerson]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Butt]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rotating inotrope therapy in a pediatric population with descompensated heart failure.]]></article-title>
<source><![CDATA[Pediatr Crit Care Med.]]></source>
<year>2011</year>
<volume>12</volume>
<page-range>57-60</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papoff]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Catesta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Versacci]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beneficial effects of levosimendan in infants with sepsis associated cardiac dysfunction: Report of 2 cases.]]></article-title>
<source><![CDATA[Pediatr Emerg Care.]]></source>
<year>2012</year>
<volume>28</volume>
<page-range>1062-5</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathieu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levosimendan in the treatment of acute heart failure, cardiogenic and septic shock: A critical review.]]></article-title>
<source><![CDATA[JICS]]></source>
<year>2011</year>
<volume>12</volume>
<page-range>15-24</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Castro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Teboul]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of levosimendan on systematic and regional hemodynamics in septic myocardial depression.]]></article-title>
<source><![CDATA[Intensive Care Med.]]></source>
<year>2005</year>
<volume>31</volume>
<page-range>638-44</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flierl]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rittirsch]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Huber-Lang]]></surname>
<given-names><![CDATA[MS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular events in the cardiomiopathy of sepsis.]]></article-title>
<source><![CDATA[Mol Med.]]></source>
<year>2008</year>
<volume>14</volume>
<page-range>327-36</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollenberg]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ahrens]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Annane]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice parameters for hemodynamic support of sepsis in adults patients: 2004 update]]></article-title>
<source><![CDATA[Crit Care Med.]]></source>
<year>2004</year>
<volume>32</volume>
<page-range>1928</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Rehberg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ertmer]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of levosimendan in sepsis and septic shock.]]></article-title>
<source><![CDATA[Curr Opin Anaesthesiol]]></source>
<year>2008</year>
<volume>21</volume>
<page-range>168-77</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shrishu]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Indira]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sunit]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levosimendan drug review.]]></article-title>
<source><![CDATA[Indian Pediatr.]]></source>
<year>2009</year>
<volume>46</volume>
<page-range>593-6</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sonnenblick]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Frishman]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[LeJemtel]]></surname>
<given-names><![CDATA[TH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dobutamine: A new synthetic cardioactive sympathetic amine.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1979</year>
<volume>300</volume>
<page-range>17-22</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vapaavouri]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Shinebourne]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[RL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of cardiovascular response to autonomic blockade in intact fetal and neonatal lambs.]]></article-title>
<source><![CDATA[Biol Neonate]]></source>
<year>1973</year>
<volume>22</volume>
<page-range>177-88</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Padbury]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Thio]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dobutamine pharmacokinetics and cardiovascular responses in critically ill neonates.]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>1992</year>
<volume>89</volume>
<page-range>47-51</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roze]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Tohier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Maingueneau]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response to dobutamina and dopamine in the hypotensive very preterm infant.]]></article-title>
<source><![CDATA[Arch Dis Child.]]></source>
<year>1993</year>
<volume>69</volume>
<page-range>59-63</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Which inotrope for which baby?]]></article-title>
<source><![CDATA[Arch Dis Child Fetal Neonatal.]]></source>
<year>2006</year>
<volume>9</volume>
<page-range>F213-20</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spear]]></surname>
<given-names><![CDATA[GS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eosinophilic explants carditis with eosinophilia: Hypersensitivity to dobutamine infusion.]]></article-title>
<source><![CDATA[J Heart Lung Transplant.]]></source>
<year>1995</year>
<volume>14</volume>
<page-range>755-60</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akhtar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mikulic]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemodynamic effect of dobutamine in patients with severe heart failure.]]></article-title>
<source><![CDATA[Am J Cardiol.]]></source>
<year>1975</year>
<volume>36</volume>
<page-range>202-5</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollenberg]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inotropes and vasopressor therapy of septic shock.]]></article-title>
<source><![CDATA[Critical Care Clin.]]></source>
<year>2009</year>
<volume>23</volume>
<page-range>781-802</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boss]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hagen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lowell]]></surname>
<given-names><![CDATA[BB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uncoupling proteins 2 and 3: Potential regulators of mitochondrial energy metabolism.]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2000</year>
<volume>49</volume>
<page-range>143-56</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspers]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uncoupling protein-2 modulates myocardial excitation-contraction coupling.]]></article-title>
<source><![CDATA[Circ Res.]]></source>
<year>2011</year>
<volume>106</volume>
<page-range>730-8</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dellinger]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock 2012.]]></article-title>
<source><![CDATA[Intensive Care Med.]]></source>
<year>2013</year>
<volume>39</volume>
<page-range>165-228</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Deutschamn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Warren]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The third international consensus definitions for sepsis and septic shock (sepsis-3).]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2016</year>
<volume>315</volume>
<page-range>801-10</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dipchand]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bharat]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Manlhiot]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective study of dobutamine stress echocardiography for the assessment of cardiac allograft vasculopathy in pediatric heart transplant recipients.]]></article-title>
<source><![CDATA[Pediatric Transplantation.]]></source>
<year>2010</year>
<volume>12</volume>
<page-range>570-6</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Losser]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Hayon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic and renal macro and microcirculatory responses to arginine vasopressin in endotoxic rabbits.]]></article-title>
<source><![CDATA[Crit Care Med.]]></source>
<year>2004</year>
<volume>32</volume>
<page-range>1891-8</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Asico]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The dopaminergic system in hypertension.]]></article-title>
<source><![CDATA[Clin Sci Lond.]]></source>
<year>2007</year>
<volume>112</volume>
<page-range>583-97</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bellomo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Finfer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: A placebo controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trial Group.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>356</volume>
<page-range>2139-43</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meier-Hellmann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bredle]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Specht]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of low dose dopamine on splanchnic blood flow and oxygen update in patients with septic shock.]]></article-title>
<source><![CDATA[Intensive Care Med.]]></source>
<year>2007</year>
<volume>23</volume>
<page-range>31</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osborn]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kluckow]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow.]]></article-title>
<source><![CDATA[J Pediatric.]]></source>
<year>2002</year>
<volume>140</volume>
<page-range>183-91</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liet]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Boscher]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gras-Leguen]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosus.]]></article-title>
<source><![CDATA[J Pediatric.]]></source>
<year>2002</year>
<volume>140</volume>
<page-range>373-5</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filippi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pezzatti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Poggi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dopamine versus dobutamine in very low birthweights infants: Endocrine effects.]]></article-title>
<source><![CDATA[Arch Dis Chil Fetal Neonatal.]]></source>
<year>2007</year>
<volume>92</volume>
<page-range>367-71</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Povoa]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Carneiro]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[OS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of vasopressor agent in septic shock mortality: Results from the Portuguese community-adquired Sepsis Study (SACiUCI study).]]></article-title>
<source><![CDATA[Crit Care Med.]]></source>
<year>2009</year>
<volume>37</volume>
<page-range>410-6</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Backer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Biston]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Devriendt]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of dopamine and norepinephrine in the treatment of shock.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2010</year>
<volume>362</volume>
<page-range>779-89</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chikanza]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
<name>
<surname><![CDATA[Petrou]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chrousos]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perturbations of arginine vasopressin secretion during inflammatory stress: Pathophysiologic implications.]]></article-title>
<source><![CDATA[Ann NY Acad Sci.]]></source>
<year>2000</year>
<volume>917</volume>
<page-range>825-34</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gottschling]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baghai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arginine vasopressin in catecholamine-refractory septic versus non106 septic shock in extremely low birth weight infants with acute renal injury.]]></article-title>
<source><![CDATA[Crit Care.]]></source>
<year>2006</year>
<volume>10</volume>
<page-range>26-30</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luckner]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dünser]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Stadlbauer]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome.]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2006</year>
<volume>10</volume>
<page-range>R40</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wernovsky]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wypij]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jonas]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1995</year>
<volume>92</volume>
<page-range>2226-35</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sethi]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vasoactive inotrope score as a tool for clinical care in children post cardiac surgery.]]></article-title>
<source><![CDATA[Indian J Crit Care Med.]]></source>
<year>2014</year>
<volume>18</volume>
<page-range>653-8</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>100.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaies]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Jeffries]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Niebler]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vasoactive-inotropic score is associated with outcome after infant cardiac surgery: An analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System Registries.]]></article-title>
<source><![CDATA[Pediatr Crit Care Med.]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>529-37</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>101.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sevketoglu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Anil]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kazanci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is an inotrope score a predictor of mortality and morbidity in children with septic shock?]]></article-title>
<source><![CDATA[Crit Care.]]></source>
<year>2015</year>
<volume>19</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>P147</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
